NanoViricides, Inc. (NNVC) is a clinical-stage company that is developing NV-387, a novel antiviral compound that will be initiating a clinical trial against MPox in late 2025/early 2026, with multiple other potential anti-viral indications. Preclinical results show that NV-387 possesses anti-viral activity against a wide range of pathogens, including respiratory syncytial virus (RSV), influenza, and measles. The company will be filing a clinical trial authorization (CTA) in order to conduct a Phase 2 clinical trial for the treatment of MPox in the Democratic Republic of Congo. In addition, the company is planning a clinical trial in India that will seek to obtain efficacy data for NV-387 against RSV, influenza, and coronaviruses in a single adaptive "basket-type" novel clinical trial design.
